KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBT Margin: 2010-2025

Historic EBT Margin for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to 6.38%.

  • TherapeuticsMD's EBT Margin rose 11003.00% to 6.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36%, marking a year-over-year increase of 25161.00%. This contributed to the annual value of -133.05% for FY2024, which is 46157.00% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's EBT Margin is 6.38%, which was down 88.86% from 57.25% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBT Margin registered a high of 268.50% during Q4 2021, and its lowest value of -4,273.85% during Q2 2022.
  • For the 3-year period, TherapeuticsMD's EBT Margin averaged around -457.60%, with its median value being -258.47% (2024).
  • In the last 5 years, TherapeuticsMD's EBT Margin crashed by 408,842bps in 2022 and then surged by 372,145bps in 2023.
  • TherapeuticsMD's EBT Margin (Quarterly) stood at 268.50% in 2021, then tumbled by 19,783bps to 70.67% in 2022, then plummeted by 38,620bps to -315.54% in 2023, then spiked by 32,798bps to 12.44% in 2024, then skyrocketed by 11,003bps to 6.38% in 2025.
  • Its last three reported values are 6.38% in Q3 2025, 57.25% for Q2 2025, and -169.97% during Q1 2025.